Prospective Observational Study to Evaluate Secukinumab Treatment Effectiveness in Pediatric Patients With Active Juvenile Enthesitis-related or Psoriatic Arthritis

Not yet recruitingOBSERVATIONAL
Enrollment

150

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

August 30, 2028

Study Completion Date

August 30, 2028

Conditions
Juvenile Idiopathic Arthritis
Interventions
OTHER

Secukinumab

This is an observational study, there is no treatment allocation.

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY